Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors
Oct 17, 2025
,
Gordon et al.
ESMO
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Preliminary Results From a Randomized, Open-Label, Phase 2 Study of Botensilimab With or Without Balstilimab in Refractory Microsatellite Stable Metastatic Colorectal Cancer With No Liver Metastases
ASCO
American Society for Clinical Oncology, Gastrointestinal (ASCO-GI)
January 25, 2025
,
Fakih, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
TPS 515: A phase II study of agenT-797 (invariant natural killer T cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma
ASCO
American Society for Clinical Oncology, Gastrointestinal (ASCO-GI)
January 23, 2025
,
Cytryn et al.
Botensilimab (Fc-enhanced anti-CTLA-4)
Fc-Enhanced Anti-CTLA-4 Antibody, Botensilimab, Enhances the Efficacy of Multiple Therapeutic Modalities in Immunotherapy-Refractory Tumor Models
SITC
Society for Immunotherapy of Cancer (SITC)
November 7, 2024
,
Levey, et al.
No items found.